Proteases esesential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents

Current Pharmaceutical Design

Volumn 13, Issue 4, 2007, Pages 405-414

  Kido, Hiroshi ^a   Okumura, Yuushi ^a   Yamada, Hiroshi ^a   Le, Trong Quang ^a   Yano, Mihiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Ambroxol; Clarithromycin; Influenza virus; Mini plasmin; Processing protease; Pulmonary surfactant; Secretory leukoprotease inhibitor; Trypsin; Tryptase Clara

Indexed keywords

AMANTADINE; AMBROXOL; ANTIOXIDANT; ANTIPAIN; ANTIVIRUS AGENT; APROTININ; BENZAMIDINE; BOWMAN BIRK INHIBITOR; CLARITHROMYCIN; IMMUNOGLOBULIN A; INTERLEUKIN 12; LEUPEPTIN; LUNG SURFACTANT; MACROLIDE; MEMBRANE FUSION PROTEIN; MUCOLYTIC AGENT; OSELTAMIVIR; PROTEINASE; PROTEINASE INHIBITOR; RIMANTADINE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; SIALIDASE INHIBITOR; SOYBEAN TRYPSIN INHIBITOR; SURFACTANT PROTEIN A; TRYPSIN; UNINDEXED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; ZANAMIVIR;

ADSORPTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BRAIN INFECTION; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; HOST CELL; HUMAN; INFLUENZA; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; RESPIRATORY TRACT INFECTION; UPREGULATION; VIROGENESIS;

EID: 33947611615     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780162971     Document Type: Article

References (58)

1. Homma M, Ohuchi M. Trypsin action on the growth of Sendai virus in tissue culture cell. J Virol 1973; 12: 1457-65.
2. Scheid A, Choppin PW. Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity by proteolytic cleavage of an inactive precursor protein of Sendai virus. Virology 1974; 57:475-90.
3. Klenk H-D, Rott R. The molecular biology of influenza virus pathogenicity. Adv Virus Res 1988; 34: 247-81.
4. Kido H, Murakami M, Oba K, Chen Y, Towatari T. Cellular proteinases trigger the infectivity of influenza A and Sendai viruses. Mol Cells 1999; 9: 235-44.
5. Sakai K, Kawaguchi Y, Kishino Y, Kido H. Electron immunohistochemical localization in rat bronchiolar epithelial cells of tryptase Clara, which determines the pneumotropism and pathogenicity of Sendai virus and influenza virus. J Histochem 1993; 41: 89-93.
6. Klenk H-D, Garten W. Host cell processing proteases controlling virus pathogenicity. Trends Microbiol 1994; 2: 39-42.
7. Gething MJ, Bye J, Skehel JJ, Waterfield MD. Nature 1980; 287: 301-6.
8. Menninger KA. Influenza and schizophrenia. An analysis of postinfluenza "dementia precox" as of 1918 and five years later. Am J Psychiatr 1926; 5: 469-529.
9. Ward A.C. Neurovirulence of influenza A virus. J Neurovirol 1996; 2: 139-51.
10. Lazarowitz SG, Goldberg AR, Choppin PW. Proteolytic cleavage by plasmin of a HA polypeptide of influenza virus: host cell activation of serum plasminogen. Virology 1973; 56: 172-80.
11. Kido H, Yokogoshi Y, Sakai K, Tashiro M, Kishino Y, Fukutomi A, Katunuma N. Isolation and characterization of a novel trypsinlike protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem 1992; 267:13573-9.
12. Murakami M, Towatari T, Ohuchi M, Shiota M, Akao M, Okumura Y, Parry MAA, Kido H. Mini-plasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai virus. Eur J Biochem 2001; 268:2847-55.
13. Towatari T, Ide M, Ohba K, Chiba Y, Murakami M, Shiota M, Kawachi M, Yamada H, Kido H. Identification of ectopic anionic trypsin I in rat lungs potentiating pneumotropic virus infectivity and increased enzyme level after virus infection. Eur J Biochem 2002; 269:1-9.
14. Chen Y, Shiota M, Ohuchi M, Towatari T, Tashiro M, Murakami M, Yano M, Yang B, Kido H. Mast cell tryptase from pig lungs triggers infection by pneumotropic Sendai and influenza viruses. Purification and characterization. Eur J Biochem 2000; 267: 3189-97.
15. Sato M, Yoshida S, Iida K, Tomozawa T, Kido H, Yamashita M. A novel influenza A virus activating enzyme from porcine lung: purification and characterization. Biol Chem 2003; 384: 219-227.
16. Tashiro M, Ciborowski P, Klenk H-D, Pulverer G, Rott R. Role of Staphylococcus protease in the development of influenza pneumonia. Nature 1987; 352: 536-7.
17. Akaike T, Maeda H. Nitric oxide and virus infection. Immunology 2000; 101: 300-8.
18. Takahashi M, Yamada T, Nakaima S, Yamamoto T. The substantia is a major target for neurovirulent influenza A virus. J Exp Med 1995; 181: 2161-9.
19. Delorme L, Middleton PJ. Influenza A virus associated with acute encephalopathy. Am J Dis Child 1979; 133: 822-4.
20. Fujimoto S, Kobayashi M, Uemura O, Iwasa M, Ando T, Katoh T, Nakamura C, Maki N, Togari H, Wada Y. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. Lancet 1998; 352: 873-5.
21. Le TQ, Kawachi M, Yamada H, Shiota M, Okumura Y, Kido H. Identification of trypsin I as a candidate for influenza A virus and Sendai virus envelope glycoprotein processing protease in rat brain. Biol Chem 2006; 387: 467-475.
22. Yao D, Kuwajima M, Chen Y, Shiota M, Okumura Y, Yamada H, Kido H. Impaired long-chain fatty acid metabolism in mitochondria causes brain vascular invasion by a non-neurotropic epidemic influenza A virus in the newborn/suckling period: implications for influenza-associated encephalopathy. Mol Cell Biochem 2006 August 8; [Epub ahead of print].
23. Beppu Y, Immamura Y, Tashiro M, Towatari T, Ariga H, Kido H. Human mucus protease inhibitor in airway fluids is a potential defensive compound against infection with influenza A and Sendai viruses. J Biochem 1997; 121: 309-16.
24. Kido H, Sakai K, Kishino Y, Tashiro M. Pulmonary surfactant is a potential endogenous inhibitor of proteolytic activation of Sendai virus and influenza virus. FEBS Lett 1993; 322: 115-9.
25. Tashiro M, Beppu Y, Sakai K, Kido H. Inhibitory effect of pulmonary surfactant on Sendai virus infection in rat lungs. Arch Virol 1996;141: 1571-7.
26. Mooren HWD, Kramps JA, Franken C, Meijer CJLM, Dickman JA. Localization of a low-molecular-weight bronchial protease inhibitor in the peripheral human lung. Thorax 1983; 38: 180-3.
27. Puchelle EJ, Hinnraski J, Tournier JM, Adnet JJ. Ultrastructural localization of bronchial inhibitor in human airways using protein A-gold technique. Biol Cell 1985; 55: 151-4.
28. Ohlsson M, Rosengren M, Tegner H, Ohlsson K. Quantification of granulocyte elastase inhibitors in human mixed saliva and pure parotid secretion. Hoppe-Seyler's Z Physiol Chem 1983; 364: 1323-8.
29. Willems LNA, Kramps JA, Stijnen T, Sterk PJ, Weening JJ, Dijkman JM. Relationship with morphologic disease of small airways and parenchyma. Am Rev Respir Dis 1989; 139: 1244-50.
30. Vogelmeier C, Hubbard RC, Fells GA, Schnebli H-P, Thompson RC, Fritz H, Crystal RG. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 1991; 87: 482-8.
31. Lee CH, Igarashi A, Hohman RJ, Kaulbach H, White MV, Kaliner MA. Distribution of secretory leukoprotease inhibitor in the human nasal airway. Am Rev Respir Dis 1993; 147: 710-6.
32. Grütter MG, Fendrich G, Huber R, Bode W. The 2.5 Å X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analyzed in its complex with bovine α-chymotrypsin. EMBO J 1988; 7: 345-51.
33. Van-Seuningen I, Davril M. Separation of the two domains of human mucus proteinase inhibitor: inhibitory activity is only located in the carboxy-terminal domain. Biochem Biophys Res Commun 1991; 179: 1587-92.
34. Kido H, Beppu Y, Imamura Y, Chen Y, Murakami M, Oba K, Towatari T. Biopolymers 1999; 51: 79-86.
35. Zhirnov OP, Golyando PB, Ovcharenko AV. Replication of influenza B virus in chicken embryos is suppressed by exogenous aprotinin. Arch Virol 1994; 135: 209-16.
36. Zhirnov OP, Vorobjeva IV, Ovcharenko AV, Klenk H-D. Intracellular cleavage of human influenza A virus hemagglutinin and its inhibition. Biochemistry 2003; 68: 1020-6.
37. Gillissen A, Scharling B, Jaworska M, Bertling A, Rasche K, Schulze-Werninghaus G. Oxidant scavenger function of ambroxol in vitro: a comparison with N-acetylcysteine. AC Res Exp Med 1997; 196: 389-98.
38. Pfeifer S, Zissel G, Kienast K, Muller-Quernheim J. Reduction of cytokine release from blood and bronchoalveolar mononuclear cells by ambroxol. Eur J Med Res 1997; 2: 129-32.
39. Gibbs BF, Schmutzler W, Vollrath IB, Brosthardt P, Braam U, Wolff HH, Zwadlo-Klarwasser G. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm Res 1999; 48: 86-93.
40. Yang B, Yao DF, Ohuchi M, Ide M, Yano M, Okumura Y, Kido H. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur Res J 2002; 19: 952-8.
41. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996; 70: 1818-27.
42. Clercq ED. Antiviral drugs in current clinical use. J Clin Virol 2004; 30: 115-33.
43. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW, Colman PM, Varghse JN, Ryan DM, Woods JM, Bethell RC, Hotham VJ, Cameron JM, Penn CR. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418-23.
44. Kim CU, Lew W, Williams MA, Wu H, Zhang L, Chen X, Escarpe PA, Mendel DB, Laver WG, Stevens RC. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem 1998; 41: 2451-60.
45. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden F, Sugaya N, Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364: 759-65.
46. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, Kim CU, Mendel DB. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS4071. Antimicrob Agents Chemother 1998; 42: 5234-41.
47. Barnett JM, Cadman A, Burrell FM, Madar SH, Lewis AP, Tisdale M, Bethell R. In vitro selection and characterization of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 1999; 265: 286-95.
48. Murphy BR, Webster RG. In: Field BN, Knipe DN Eds, Virology. Philadelphia, Lippincott-Raven. 1996; 1397-445.
49. Liew FY, Russell SM, Appleyard G, Brand CM, Beale J. Crossprotection in mice infected with influenza A virus by the respiratory route is correlated with local IgA rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol 1984; 14: 350-6.
50. Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, Nakajima K, Suzuki Y, Aizawa C, Kurata T. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 1996; 156: 3892-900.
51. Wright PF, Murphy BR, Kervina M, Lawrence EM, Phelan MA, Karzon DT. Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect Immun 1983; 40: 1092-5.
52. Tsurita M, Kurokawa M, Imakita M, Fukuda Y, Watanabe Y, Shiraki K. Early augmentation of interleukin (IL)-12 level in the airway of mice administered orally with clarithromycin or intranasally with IL-12 results in alleviation of influenza infection. J Pharmacol Exp Ther 2001; 298: 362-8.
53. Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E, McGhee JR. IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol 1999; 162: 122-8.
54. Hayden FG. Perspectives on antiviral use during pandemic influenza. Phil Trans R Soc London 2001; 356: 1877-84.
55. Kido H, Okumura Y, Yamada H, Mizuno D, Higashi Y, Yano M. Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential. Biol Chem 2004; 385: 1029-34.
56. Matsuno H. Alpha2-antiplasmin on cardiovascular diseases. Curr Pharm Des 2006; 12(7): 841-7.
57. Takahashi H, Sano H, Chiba H, Kuroki Y. Pulmonary surfactant proteins A and D: innate immune functions and biomarkers for lung diseases. Curr Pharm Des 2006; 12(5): 589-598.
58. Tsai C. H, Lee P. Y, Stollar V, Li M. L. Antiviral therapy targeting viral polymerase. Curr Pharm Des 2006; 12(11): 1339-55.